Role of systemic inflammatory response markers in urological malignancy

Ohno, Yoshio

doi:10.1111/iju.13801

Cited by 61 publications

(63 citation statements)

References 164 publications

(361 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PNI is a combination of serum albumin and peripheral blood lymphocyte count. High values of PNI are associated with a good prognosis in cancer patients [84]. Studies evaluating the prognostic value of PNI in patients with RCC are few but confirm these results [129][130][131][132][133][134][135].…”

Section: Inflammation As Prognostic Factormentioning

confidence: 88%

See 1 more Smart Citation

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Brighi

Farolfi

Conteduca

et al. 2019

Cancers

View full text Add to dashboard Cite

Treatment options for metastatic renal cell carcinoma (RCC) have been expanding in the last years, from the consolidation of several anti-angiogenic agents to the approval of immune checkpoint inhibitors (ICIs). The rationale for the use of immunomodulating agents derived from the observation that RCC usually shows a diffuse immune-cell infiltrate. ICIs target Cytotoxic T Lymphocytes Antigen 4 (CTLA-4), programmed death 1 (PD-1), or its ligand (PD-L1), showing promising therapeutic efficacy in RCC. PD-L1 expression is associated with poor prognosis; however, its predictive role remains debated. In fact, ICIs may be a valid option even for PD-L1 negative patients. The establishment of valid predictors of treatment response to available therapeutic options is advocated to identify those patients who could benefit from these agents. Both local and systemic inflammation contribute to tumorigenesis and development of cancer. The interplay of tumor-immune status and of cancer-related systemic inflammation is pivotal for ICI-treatment outcome, but there is an unmet need for a more precise characterization. To date, little is known on the role of inflammation markers on PD-1 blockade in RCC. In this paper, we review the current knowledge on the interplay between inflammation markers, PD-1 axis, and anti-angiogenic agents in RCC, focusing on biological rationale, implications for treatment, and possible future perspectives.

show abstract

Section: Inflammation As Prognostic Factormentioning

confidence: 88%

“…These cytokines are produced in various cells, including inflammatory cells and cancer cells. Thus, serum CRP concentration might be elevated due to hepatic stimulation by cancer-cell-derived inflammatory cytokines [84].…”

Section: Inflammation As Prognostic Factormentioning

confidence: 99%

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Brighi

Farolfi

Conteduca

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…To make right treatment decisions for the right patient at right timing, a detailed prognosis estimation is needed. Recent studies have shown that elevated tumor markers, such as LDH and ALP, and some in ammatory markers are poor prognostic factors for CRPC [6]. Zhao et al developed a prognostic nomogram for CRPC among Chinese patients using a 449-patient cohort [18].…”

Section: Discussionmentioning

confidence: 99%

The Development and Validation of a Prognostic Nomogram and Nomogram Application Software Among Men Treated with Abiraterone Acetate and/or Enzalutamide for Metastatic Castration-resistant Prostate Cancer

Kawahara

Saigusa

Yoneyama

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:With widespread medication choices for metastatic castration-resistant prostate cancer (mCRPC) is now available, on the other hand biomarker to predict the efficacy of each mCRPC treatment has not been established.Objective:This study developed prognostic nomogram to predict prognosis in CRPC patients who received abiraterone acetate (ABI) and/or enzalutamide (ENZ).Design, Setting, and Participants:A total of 568 mCRPC patients received ABI and/or ENZ from 2012 to 2017 were enrolled in this study. We developed prognostic nomogram based on the risk factors by Cox proportional hazards regression model.Outcome Measurements and Statistical Analysis:The nomogram was also assessed for discriminatory ability with the concordance index (C-index). We repeated 5-fold cross-validation 2000 times to estimate the C-index and reported the means of the estimated C-index for the training and validation sets. And we also developed nomogram application software (app) based on this nomogram.Results and Limitations:The median overall survival (OS) was 24.7 months. A multivariable analysis showed that the time to CRPC, pre-chemotherapy, baseline PSA, baseline ALP, and baseline LDH were independent risk factors for the OS (HR: 0.521, 1.681, 1.439, 1.827, 12,123, p:0.001, 0.001, <0.001, 0.019, <0.001)). C-index was 0.72 in training cohort and 0.71 in validation cohort.Conclusion:We developed nomograms to predict the OS for Japanese mCRPC patients who received ABI and/or ENZ. The advent of mCRPC prognosis prediction app will facilitate greater accessibility for clinical use.Patient SummaryThis study developed and validated a nomogram for predicting the prognosis of mCRPC patients who receive ABI/ENZ treatment using clinical information. This study also developed mobile app to facilitate clinical usage.

show abstract

“…Numerous clinical prognostic or predictive factors have been identi ed based on clinical trials and retrospective univariate or multivariate analysis, including performance status, appearing symptoms, and paraneoplastic syndromes [6]. Besides, laboratory values are also used for prognosis, such as serum protein, corrected calcium, erythrocyte sedimentation rate, and neutrophil to lymphocyte ratio [7,8].…”

Section: Introductionmentioning

confidence: 99%

Pre-treatment De Ritis ratio serves as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

Peng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Previous studies have evaluated the associations of aspartate transaminase to alanine transaminase (De Ritis) ratio with clinical outcome of renal cell carcinoma (RCC), but the findings are inconsistent. We therefore performed this meta-analysis to explore the prognostic value of the pre-treatment De Ritis ratio in patients with RCC.Methods PubMed, EMBASE, Science and Cochrane Library were searched systematically to identify all eligible studies as of February 2020. The hazard ratio (HR) with 95% confidence interval (CI) were extracted to evaluate their correlation.Results A total of 5,025 patients from 8 studies were included in the meta-analysis. Patients with an increased pre-treatment De Ritis ratio had worse overall survival (HR = 1.52, 95% CI 1.27 to 1.82, P < 0.001), cancer-specific survival (HR = 1.81, 95% CI 1.47 to 2.23, P < 0.001), progression-free survival (HR = 1.24, 95% CI 1.05 to 1.47, P = 0.011), and metastasis-free survival (HR = 1.61, 95% CI 1.25 to 2.07, P < 0.001). Subgroup analysis according to disease stage and cut-of value revealed that De Ritis ratio had a significant prognostic value for OS and PFS in all subgroups.Conclusion The available evidence suggests that an increased De Ritis ratio was significantly correlated with worse survival in patients with RCC. Pre-treatment De Ritis ratio may serve as a potential prognostic biomarker in patients with RCC, but further studies are warranted to support these results.

show abstract

Role of systemic inflammatory response markers in urological malignancy

Cited by 61 publications

References 164 publications

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

The Development and Validation of a Prognostic Nomogram and Nomogram Application Software Among Men Treated with Abiraterone Acetate and/or Enzalutamide for Metastatic Castration-resistant Prostate Cancer

Pre-treatment De Ritis ratio serves as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

Contact Info

Product

Resources

About